Abstract

Glass vials are the most widely used primary containers for the packaging of parenteral products due to their optical clarity, general inertness, and hermetic properties, but under certain circumstances, they can pose safety concerns. Most of these issues are related to the potential formation of glass particulates through delamination or precipitation, resulting from the chemical interaction between the drug product and the inner surface of the glass vial. Hence, it is imperative for pharmaceutical companies to conduct product-vial compatibility studies to determine the appropriate packaging/container closure system. To support this development activity, scientists need to develop analytical methods to detect subvisible glass particulates in parenteral products, along with the appropriate positive controls, to facilitate detection and identification. This paper outlines the utilization of coaxial/episcopic and oblique illumination microscopy, combined with spectroscopic techniques, to detect thin glass particulates generated from a modified procedure. It also showcases the importance of angle-dependent lighting in visualizing positive control samples containing thin glass particulates. The analytical microscopy techniques discussed in this paper can assist scientists in selecting suitable container closure systems for developing parenteral products.

Details

Title
Analytical microscopy techniques using coaxial and oblique illuminations to detect thin glass particulates generated from glass vials for parenteral drug products
Author
Sanni, Adedayo M. 1 ; Opalade, Adedamola A. 1 ; Shamirian, Armen 2 ; Mattson, Spencer 3 ; Driscoll, Eric 3 ; St. Martin, Michael 3 ; Mohan, Shikhar 1 ; Trimmer, Brooke 1 ; Bunch, Tarq 3 ; Ovadia, Robert 4 ; Yoon, Jungjoo 1 ; Ma, Sarina 5 ; Foti, Chris 1 

 Gilead Sciences Inc, Analytical Development and Operations, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634) 
 Gilead Sciences Inc, Analytical Development and Operations, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634); ORIC Pharmaceuticals Inc., South San Francisco, USA (GRID:grid.418227.a) 
 Gilead Sciences Inc, Development and Technical Services, La Verne, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634) 
 Gilead Sciences Inc, Process Technologies and Development, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634) 
 Gilead Sciences Inc, Pharmaceutical Development and Technology, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634) 
Pages
9
Publication year
2024
Publication date
Dec 2024
Publisher
Springer Nature B.V.
ISSN
22875123
e-ISSN
22874445
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3119853755
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.